CEFOTAXIME FOR INJECTION USP 500 MG — DIN 02097184
CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG · NOVOPHARM LIMITED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is CEFOTAXIME FOR INJECTION USP?
CEFOTAXIME FOR INJECTION USP 500 MG contains CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02097184, held by NOVOPHARM LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled pre market, status dated 16-Oct-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CEFOTAXIME FOR INJECTION USP used for?
Lower respiratory tract, urinary tract, skin, intra-abdominal, gynecological, and CNS infections (meningitis); bacteremia/septicemia; perioperative prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG cost around the world?
CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 15 | 19 | ZAR███.██ |
| Saudi Arabia | public | 18 | 18 | SAR███.██ |
| Morocco | PPV (public price) | 5 | 10 | MAD███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
61 pack listings across 51 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | Vials containing 500 mg, 1 g, or 2 g of cefotaxime base. |
| Storage | Dry powder: 15-25°C, protected from light. Reconstituted: 24h at room temperature (25°C) or 48h refrigerated. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Biosimilar biologic | No |
|---|
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02097184 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2097184 |
| Brand name | CEFOTAXIME FOR INJECTION USP |
| Generic / active ingredient | CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG |
| Market authorization holder | NOVOPHARM LIMITED |
| Current status | CANCELLED PRE MARKET |
| Status date | 16-Oct-2015 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 1-2g every 8-12h (up to 12g/day). Neonates: 50mg/kg every 8-12h. Infants/Children: 50-180mg/kg/day. Administered IV or IM. Prophylaxis: 1g 30-90 min pre-op.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cefotaxime sodium, cephalosporins, or the group of penicillin antibiotics.
Warnings and precautions
Risk of serious hypersensitivity reactions; Clostridium difficile-associated disease (CDAD); cephalosporin-associated hemolytic anemia; potential for granulocytopenia during long-term use.
What else is CEFOTAXIME FOR INJECTION USP called?
The same molecule, CEFOTAXIME (CEFOTAXIME SODIUM) : 500 MG, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CETAXON | Latin | Morocco |
| Kefotax | Latin | Morocco, South Africa |
| CEFOTAX | Latin | Bahrain |
| CLAFORAN | Latin | Morocco |
| Oritaxim | Latin | South Africa |
| KEFOTAX IM | Latin | Morocco |
| KEFOTAX IV | Latin | Morocco |
| Klafotaxim | Latin | South Africa |
| SEFOXIME | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.